Christopher Almario, MD, MSHPM, co-author of a recent article examining the cost-effectiveness of various approaches for preventing transmission of carbapenem-resistant Enterobacteriaceae (CRE) through ERCP endoscopes, discusses the genesis of the study and the finding that newly issued FDA recommendations for endoscope reprocessing were most cost-effective compared to the other approaches studied. Dr. Almario explains why a “do nothing strategy” was not included in the model, and addresses other underlying assumptions of the analysis. (20:39)